69f73cc3_anderbilt_Ingram_Cancer_Center__Trial_Type
[Protocol No. & Open Date] VICCURO14100 03/24/2015 [Summary] A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared with Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer after Failure with Platinum-Containing Chemotherapy [Trial Type] 
Treatment Bladder
Urologic / Genitourinary Cancers - Vanderbilt-Ingram Cancer Center
Trial Type